CXCL10 and head and neck squamous cell carcinoma: A heightened IP-10 production was observed in 13 out of 23 HNSCC samples when treated with cetuximab and pembrolizumab plus IFN-γ, which led to IP-10 levels exceeding those induced by IFN-γ treatment alone.